Search

Home > Lung Cancer Considered > FDA Approval: KEYNOTE 483, Pembrolizumab plus Chemotherapy for Mesothelioma
Podcast: Lung Cancer Considered
Episode:

FDA Approval: KEYNOTE 483, Pembrolizumab plus Chemotherapy for Mesothelioma
Category: Science & Medicine
Duration: 00:22:39
Publish Date: 2024-09-18 18:39:03
Description: In a special episode of Lung Cancer Considered, host Dr. Stephen Liu discuss the recent FDA approval of pembrolizumab plus platinum and pemetrexed for mesothelioma, based on the phase III KEYNOTE 483 study. Guest: Dr. Ibiayi Dagogo-Jack is a thoracic oncologist from Massachusetts General Hospital and Assistant Professor at Harvard Medical School Guest: Dr. Quincy Chu is a thoracic oncologist at the University of Alberta Cross Cancer Institute’s New Drug Development Program and CCTG Investigational New Drug Committee Chair
Total Play: 0